Spicing it up

The high conversion rate of curcumin prodrug TBP1901 to curcumin in bone marrow warrants its clinical application for diseases growing in the marrow like multiple myeloma and leukemia. The natural polyphenol curcumin has shown promising efficacy with tumors in a number of preclinical models.
Credit: KyotoU / Global Comms

Prodrug curcumin shows clinical potential in mice.

Curcumin, a natural molecule related to turmeric, has been used to treat cancer patients in cancer clinical studies. While it has documented antitumor effects, challenges involving its chemistry have caused drug development to lag.

Now, a team of researchers at Kyoto University has developed a prodrug form of curcumin, TBP1901, that has shown anti-tumor effects without toxicities.

“Curcumin has long been used as a spice or food coloring, so we expect to see minimal side effects,” says lead author Masashi Kanai.

The natural polyphenol curcumin has shown promising efficacy with tumors in a number of preclinical models. Such studies have reported anecdotal evidence with cancer patients of curcumin’s effect in oral form.

However, until now the poor bioavailability and low stability of curcumin have been roadblocks to its clinical application.

Kanai’s team has found a possible detour around the problem by deductively identifying the enzyme GUSB for its key role in TBP1901 conversion to curcumin. The researchers hypothesized that this conversion would not be observed in mice with genetically impaired GUSB. They also confirmed, using a CRISPR-Cas9 screen method, that curcumin also has essential therapeutic targets.

“The high conversion rate of TBP1901 to curcumin in bone marrow warrants its clinical application for diseases growing in the marrow like multiple myeloma and leukemia,” notes Kanai.

The paper “Pharmacologic characterization of TBP1901, a prodrug form of aglycone curcumin, and CRISPR-Cas9 screen for therapeutic targets of aglycone curcumin” appeared on 10 October 2022 in European Journal of Pharmacology, with doi: 10.1016/j.ejphar.2022.175321

About Kyoto University

Kyoto University is one of Japan and Asia’s premier research institutions, founded in 1897 and responsible for producing numerous Nobel laureates and winners of other prestigious international prizes. A broad curriculum across the arts and sciences at both undergraduate and graduate levels is complemented by numerous research centers, as well as facilities and offices around Japan and the world. For more information, please see: http://www.kyoto-u.ac.jp/en

Journal: European Journal of Pharmacology
DOI: 10.1016/j.ejphar.2022.175321
Method of Research: Experimental study
Subject of Research: Animals
Article Title: Pharmacologic characterization of TBP1901, a prodrug form of aglycone curcumin, and CRISPR-Cas9 screen for therapeutic targets of aglycone curcumin
Article Publication Date: 10-Oct-2022
COI Statement: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Tadashi Hashimoto is the chief executive officer of Therabiopharma Inc. Atushi Imaizumi is the senior vice president of Therabiopharma Inc. Tomoyuki Abe, Hitomi Ozawa-Umeta, Atsuhiro Kishimoto, and Yasuhiro Katsuura are employees of Therabiopharma Inc. Masashi Kanai. and Hideaki Kakeya own equity and they are the scientific consultants of Therabiopharma Inc.

Media Contact

Jake G. Tobiyama
Kyoto University
tobiyama.gakuji.6y@kyoto-u.ac.jp

www.kyoto-u.ac.jp

Media Contact

Jake G. Tobiyama
Kyoto University

All latest news from the category: Life Sciences and Chemistry

Articles and reports from the Life Sciences and chemistry area deal with applied and basic research into modern biology, chemistry and human medicine.

Valuable information can be found on a range of life sciences fields including bacteriology, biochemistry, bionics, bioinformatics, biophysics, biotechnology, genetics, geobotany, human biology, marine biology, microbiology, molecular biology, cellular biology, zoology, bioinorganic chemistry, microchemistry and environmental chemistry.

Back to home

Comments (0)

Write a comment

Newest articles

The Microprocessor inside you

It’s a big year for microRNAs. The 2024 Nobel Prize in Physiology or Medicine went to Victor Ambros and Gary Ruvkun, who discovered the first microRNA in 1993. Today, we…

To build better fiber optic cables, ask a clam

Heart cockles have shells with built-in skylights to let in light for symbiotic algae. Since the first fiber optic cables rolled out in the 1970s, they’ve become a major part…

Lifesaver under the skin

Defibrillator with sternum electrode implanted for the first time at Göttingen University Medical Center to prevent sudden cardiac death. At the Heart Center of the University Medical Center Göttingen (UMG),…